卡培他滨联合FOLFOX方案及贝伐珠单抗治疗晚期结肠癌的效果及对免疫功能的影响  

Effect of capecitabine combined with FOLFOX regimen and bevacizumab in the treatment of advanced colorectal cancer and its impact on immune function

作　　者：折桐 ZHE Tong(Department of Oncology,People′s Hospital of Zhongwei,Ningxia Hui Autonomous Region,Zhongwei 755000,China)

机构地区：[1]宁夏回族自治区中卫市人民医院肿瘤科,755000

出　　处：《临床合理用药》2024年第36期21-24,共4页Chinese Journal of Clinical Rational Drug Use

摘　　要：目的观察卡培他滨联合FOLFOX方案及贝伐珠单抗治疗晚期结肠癌的临床效果及对免疫功能的影响。方法按照双色球随机分组法将2020年3月—2022年3月中卫市人民医院收治的晚期结肠癌患者80例分为二联方案组(采取FOLFOX方案与贝伐珠单抗治疗)和三联方案组(采取卡培他滨联合FOLFOX方案与贝伐珠单抗治疗),每组40例。2组均治疗3个周期(21 d为1个周期)。比较2组近期疗效,治疗前后免疫功能指标(CD3~(+)、CD4~(+)、CD4~(+)/CD8~(+))、肿瘤标志物[糖类抗原(CA)724、CA242、甲胎蛋白(AFP)]、营养指标,不良反应。结果三联方案组疾病控制率高于二联方案组(82.50%vs.62.50%,χ^(2)=4.013,P=0.045)。治疗3个周期后,2组CD3~(+)、CD4~(+)、CD4~(+)/CD8~(+)均较治疗前升高,且三联方案组高于二联方案组(P<0.01);2组血清CA724、CA242、AFP水平均较治疗前降低,且三联方案组低于二联方案组(P<0.01);2组白蛋白、血红蛋白、血清铁、叶酸水平均较治疗前升高,且三联方案组高于二联方案组(P<0.01)。三联方案组与二联方案组各不良反应发生率比较,差异无统计学意义(P>0.05)。结论卡培他滨联合FOLFOX方案及贝伐珠单抗治疗晚期结肠癌的效果显著,可有效抑制肿瘤进展,提升机体免疫功能,改善营养状况,且具有较高的安全性。Objective To observe the clinical effect of capecitabine combined with FOLFOX regimen and bevacizumab in the treatment of advanced colorectal cancer and its impact on immune function.Methods According to the double-color ball random grouping method,80 patients with advanced colorectal cancer admitted to People′s Hospital of Zhongwei from March 2020 to March 2022 were divided into the two-drug regimen group(received FOLFOX regimen and bevacizumab)and the three-drug regimen group(received capecitabine combined with FOLFOX regimen and bevacizumab),with 40 patients in each group.Both groups were treated for 3 cycles(21 days per cycle).The short-term efficacy,immune function indicators(CD3+,CD4+,CD4+/CD8+),tumor markers(CA724,CA242,AFP),nutritional indicators before and after treatment,and adverse reactions were compared between the two groups.Results The disease control rate in the three-drug regimen group was higher than that in the two-drug regimen group(82.50%vs.62.50%,χ^(2)=4.013,P=0.045).After 3 cycles of treatment,CD3+,CD4+,and CD4+/CD8+increased in the two groups compared with those before treatment,and those in the three-drug regimen group were higher than the two-drug regimen group(P<0.01);Serum levels of CA724,CA242,and AFP decreased in the two groups compared with those before treatment,and those in the three-drug regimen group were lower than the two-drug regimen group(P<0.01);Albumin,hemoglobin,serum iron,and folate levels increased in the two groups compared with those before treatment,and those in the three-drug regimen group were higher than the two-drug regimen group(P<0.01).There was no statistically significant difference in the incidence of adverse reactions between the three-drug regimen group and the two-drug regimen group(P>0.05).Conclusion Capecitabine combined with FOLFOX regimen and bevacizumab is effective in the treatment of advanced colorectal cancer,it can effectively inhibit tumor progression,enhance immune function,improve nutritional status,and with higher safety.

关 键 词：晚期结肠癌 卡培他滨 FOLFOX方案 贝伐珠单抗 免疫功能 临床疗效 

分 类 号：R735.35[医药卫生—肿瘤]